Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Bioavailability of Daclatasvir and Asunaprevir Formulations
NCT02323594Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of daclatasvir and asunaprevir in Hepatitis C (HCV) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 96 hours, Area under the concentration-time curve from time zero extrapolated to infinite time at 96 hours and 3 more. Started Dec 2014; status: completed.
02
Drugs
daclatasvirasunaprevir
03
Conditions
Hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02323594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323594.